Publications by authors named "Edward M Chan"

Claim this Profile
E
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.
Nizar J Bahlis, Caitlin L Costello, Noopur S Raje, Moshe Y Levy, Bhagirathbhai Dholaria, Edward M Chan

Nat Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.
Jonathan W Goldman, Lee S Rosen, Anthony W Tolcher, Kyriakos Papadopoulos, Muralidhar Beeram, Edward M Chan

Invest New Drugs· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients.
Sonya C Tate, Amanda K Sykes, Palaniappan Kulanthaivel, Edward M Chan, P Kellie Turner

Clin Pharmacokinet· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.
Yutaka Fujiwara, Kenji Tamura, Shunsuke Kondo, Yuko Tanabe, Satoru Iwasa, Edward Michael Chan

Cancer Chemother Pharmacol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Amita Patnaik, Lee S Rosen, Sara M Tolaney, Anthony W Tolcher, Jonathan W Goldman, Edward M Chan

Cancer Discov· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.
Amita Patnaik, Paul Haluska, Anthony W Tolcher, Charles Erlichman, Kyriakos P Papadopoulos, Edward M Chan

Clin Cancer Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.
Shubham Pant, Suzanne F Jones, Carla D Kurkjian, Jeffrey R Infante, Kathleen N Moore, Edward M Chan

Eur J Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Lawrence M Gelbert, Shufen Cai, Xi Lin, Concepcion Sanchez-Martinez, Miriam Del Prado, Edward M Chan

Invest New Drugs· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
Vipin Yadav, Teresa F Burke, Lysiane Huber, Robert D Van Horn, Youyan Zhang, Sean G Buchanan, Edward M Chan

Mol Cancer Ther· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts.
Sonya C Tate, Shufen Cai, Rose T Ajamie, Teresa Burke, Richard P Beckmann, Edward M Chan

Clin Cancer Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity.
Robert M Campbell, Bryan D Anderson, Nathan A Brooks, Harold B Brooks, Edward M Chan

Mol Cancer Ther· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group.
Hamid Sayar, Rebecca J Chan, Christie M Orschell, Edward M Chan, Zhangsheng Yu

Leuk Res· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants.
Zhenyun Yang, Takako Kondo, Cara S Voorhorst, Sarah C Nabinger, Leila Ndong, Edward M Chan, Rebecca J Chan

Mol Cell Biol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MOZ and MOZ-CBP cooperate with NF-kappaB to activate transcription from NF-kappaB-dependent promoters.
Edward M Chan, Rebecca J Chan, Elisha M Comer, Robert J Goulet, Colin D Crean

Exp Hematol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AML1-FOG2 fusion protein in myelodysplasia.
Edward M Chan, Elisha M Comer, Frank C Brown, Kathleen E Richkind, Melissa L Holmes, Rebecca J Chan

Blood· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis